Do you want to read an article? Please log in or register.
Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials
Lipid-Lowering Drugs
Related content
Cardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesLipid-Lowering Drugs
Alirocumab Treatment and Achievement of Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials
J Am Heart Assoc.
Bays HE, Leiter LA, Colhoun HM, Thompson D, Bessac L, Pordy R, Toth PP
doi: 10.1161/JAHA.117.005639.
RECOMMENDED
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials
Atherosclerosis.
Ray KK, Vallejo-Vaz AJ, Ginsberg HN, Davidson MH, Louie MJ, Bujas-Bobanovic M, Minini P, Eckel RH, Cannon CP
doi: 10.1016/j.atherosclerosis.2019.06.896.
RECOMMENDED
Lipid-Lowering Drugs
Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control
Atherosclerosis.
Vallejo-Vaz AJ, Ray KK, Ginsberg HN, Davidson MH, Eckel RH, Lee LV, Bessac L, Pordy R, Letierce A, Cannon CP
doi: 10.1016/
Cardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesLipid-Lowering DrugsTherapy and Intervention
Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials
Atherosclerosis.
Kereiakes DJ, Lepor NE, Gerber R, Veronica Lee L, Elassal J, Thompson D, Michael Gibson C
doi: 10.1016/j.atherosclerosis.
Lipid-Lowering Drugs
Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials.
J Am Coll Cardiol.
Robinson JG, Rosenson RS, Farnier M, Chaudhari U, Sasiela WJ, Merlet L, Miller K, Kastelein JJ
doi: 10.1016/j.jacc.2016.11.037.
Lipid-Lowering Drugs
Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome and without diabetes: Pooled data from 10 phase 3 trials
Diabetes Obes Metab.
Henry RR, Müller-Wieland D, Taub PR, Bujas-Bobanovic M, Louie MJ, Letierce A, Ginsberg HN
doi: 10.1111/dom.13273.
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial
JAMA Cardiol.
Giugliano RP, Wiviott SD, Blazing MA, De Ferrari GM, Park JG, Murphy SA, White JA, Tershakovec AM, Cannon CP, Braunwald E
doi: 10.1001/jamacardio.
RECOMMENDED
Lipid-Lowering Drugs
Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies
★ 2
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
J Am Heart Assoc.
Toth PP, Jones SR, Monsalvo ML, Elliott-Davey M, López JAG, Banach M
doi: 10.1161/JAHA.119.014129.
Lipid-Lowering Drugs
Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis
JAMA Cardiol.
Sabatine MS, Wiviott SD, Im K, Murphy SA, Giugliano RP
doi: 10.1001/jamacardio.2018.2258